Company intelligence / Profile preview

Vessix Vascular

Laguna Hills, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

Vessix Vascular developed a radiofrequency balloon catheter system for renal denervation to treat uncontrolled hypertension. Its lead product, the V2 Renal Denervation System, received CE Mark approval in Europe and Therapeutic Goods Administration approval in Australia. The company initiated postmarket surveillance studies but had not launched commercially in the US before being acquired by Boston Scientific for up to $425 million.

Therapeutic areas: Cardiovascular
Modalities: DeviceRadiofrequency ablation deviceBalloon catheter technology
Industry: Surgical Medical Devices

Partnerships

OrbiMed Advisors (investor)Edmond de Rothschild Investment Partners (investor)NeoMed Management (investor)

Beyond the preview

Go deeper on Vessix Vascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vessix Vascular.

Explore the full profile